FolkmanJ.: Angiogenesis in cancer, vascular, rheumatoid and other disease.Nature Medicine, 1: 27–31, 1995.
2.
FoxS.B., GaspariniG., HarrisA.L.: Angiogenesis: pathological, prognostic, and growth- factor pathways and their link to trial design and anticancer drugs.Lancet Oncology, 2: 278–289, 2001.
3.
O'ReillyM.S., HolmgrenL., ShingY., ChenC., RosenthalR.A., MosesM., LaneW.S., CaoY., SageE.H., FolkmanJ.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.Cell, 79: 315–328, 1994.
4.
ChaplinD.J., DoughertyG.J.: Tumor Vasculature as a target for cancer therapy.British Journal of Cancer, 80: 57–64, 1999.
5.
TarabolettiG., MargosioB.: Antiangiogenic and antivascular therapy for cancer.Current Opinions in Pharmacology, 1: 378–384, 2001.
6.
O'ReillyM.S., BohemT., ShingY., VassiosG., LaneW.S., FlynnE., BirkheadJ.R., OlsenB.R., FolkmanJ.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.Cell, 88: 277–285, 1997.
7.
KungA.L., WangS., KlcoJ.M., KaelinW.G., LivingstonD.M.: Suppression of tumor growth through disruption of hypoxia-inducible transcription.Nature Medicine, 6: 1335–1340, 2000.
8.
EliceiriB.P., ChereshD.: The role of v integrins during angiogenesis/insights into potential mechanisms of action and clinical development.Journal of Clinical Investigation, 103: 1227–1230, 1999.
9.
GiavazziR., NicolettiM.I.: Small molecules in anti-angiogenic therapy.Current Opinions in Drug Discovery and Development (in press).
10.
FerraraN.: Molecular and biological properties of vascular endothelial growth factor.Journal of Molecular Medicine, 77: 1269–1299, 1999.
11.
CherringtonJ.M., StrawnL.M., ShawverL.K.: New paradigms for the treatment of cancer.Advances in Cancer Research, 79: 1–38, 2000.
12.
GiavazziR., TarabolettiG.: Preclinical development of metalloproteases inhibitors in cancer therapy.Critical Reviews in Oncology-Hematology, 37: 53–60, 2001.
13.
HidalgoM., EckhardtS.G.: Development of matrix metalloproteinase inhibitors in cancer therapy.Journal of the National Cancer Institute, 93: 178–193, 2001.
14.
BergersG., JavaherianK., LoK.M., FolkmanJ., HanahanD.: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.Science, 284: 808–182, 2000.
15.
KakejiY., TeicherB.A.: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents.Investigational New Drugs, 15: 39–48, 1997.
16.
GiavazziR., GarofaloA., FerriC., LucchiniV., BoneE.A., ChiariS., BrownP.D., NicolettiM.I., TarabolettiG.: Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumour activity of cisplatin in ovarian carcinoma xenografts.Clinical Cancer Research, 4: 985–992, 1998.
17.
BelottiD., VerganiV., DrudisT., BorsottiP., PitelliM.R., VialeG., GiavazziR., TarabolettiG.: The microtubules affecting drug paclitaxel has anti-angiogenic activity.Clinical Cancer Research, 2: 1843–1850, 1996.
18.
KlementJ., BaruchelS., RakJ., ManS., ClarkK., HicklinD.J., BohlenP., KerbelR.S.: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity.Journal of Clinical Investigation, 105: R15–R24, 2000.
